Biogen announces planned hemophilia branch
The new company will continue to establish therapies to treat hemophilia A, while Biogen will be dedicated to developing novel treatments for neurology concerns.
“We expect that the new company will be a leader in discovering, developing and commercializing innovative therapies for hemophilia, built on remarkable science and a deep understanding of how to continually improve treatment for patients,” Biogen CEO George Scangos said. “Our expanding hemophilia business continues to perform very well. Eloctate and Alprolix provide meaningful benefits for people living with hemophilia and continue to gain market share. We believe that the best way to realize the full potential of this growing and vital business is to enable it to operate independently with a management team dedicated to providing therapies to people living with hemophilia.”
Biogen leaders see this as an opportunity to develop two companies that are focused on two different branches of health while still using its strong foundation to push for greater improvements in the health industry.
“For Biogen, our mission remains unchanged: we continue to aspire to have the greatest impact on patients of any biotechnology company in the history of our industry,” Scangos said. “Biogen is poised to make a tremendous difference in the lives of millions of people suffering from diseases with a neuronal etiology, including neurodegeneration, neuromuscular disorders, neuropathic pain and ophthalmological indications. Our depth of knowledge in neuroscience and neurology is remarkable. The biological bases of many of these diseases are becoming clear, and we believe we are very well positioned to be a leader in these important areas.”
Organizations in this story
Biogen 225 Binney St Cambridge, MA - 02142